Fate Therapeutics (FATE) Free Cash Flow (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Free Cash Flow data on file, last reported at -$31.1 million in Q1 2026.

• Quarterly Free Cash Flow rose 9.87% year-over-year to -$31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.6 million (up 12.47% YoY) and the FY2025 annual result came in at -$112.0 million, up 8.92% from the prior year.
• Free Cash Flow retreated to -$31.1 million in Q1 2026, from -$28.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$23.8 million in Q3 2025 to a low of -$70.0 million in Q2 2022.
• A 5-year average of -$38.5 million and a median of -$32.4 million in 2024 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 59.48% in 2022, down 228.52% in 2022.
• Tracing FATE's Free Cash Flow over 5 years: stood at -$47.6 million in 2022, then advanced by 10.37% to -$42.6 million in 2023, then surged by 34.49% to -$27.9 million in 2024, then fell by 3.39% to -$28.9 million in 2025, then slipped by 7.59% to -$31.1 million in 2026.
• The last three Free Cash Flow figures came in at -$31.1 million (Q1 2026), -$28.9 million (Q4 2025), and -$23.8 million (Q3 2025), per Business Quant data.